Efficacy and Tolerability of RAP-219, a Potential First-in-Class Negative Allosteric Modulator of γ8 TARP: Impact on RNS Long Episodes and Clinical Seizures

William W. Motley, MD, DPhil; Imran H. Quraishi, MD, PhD; Neal M. Nolan, MD; Daniel Friedman, MD; Patrick Landazuri, MD; Vikram R. Rao, MD; Kathryn A. Davis, MD; Bradley S. Galer, MD; Nancy Wyant, BA; Martha J. Morrell, MD; Arnold R. Gammaitoni, PharmD; Jacqueline A. French, MD